

Special Issue

Cardiac Arrhythmias: Technological Frontiers, Therapeutic Approaches and Future Directions

Message from the Guest Editors

This Special Issue, “Cardiac Arrhythmias: Technological Frontiers, Therapeutic Approaches and Future Directions,” aims to explore the rapidly evolving landscape of arrhythmia research, from fundamental mechanisms to translational breakthroughs. We are witnessing a paradigm shift driven by innovations across the digital and experimental spectrum. Digital health—including e-cardiology, telemonitoring, and artificial intelligence—is providing unprecedented insights into arrhythmia prediction, detection, and risk stratification. Concurrently, the devices landscape and the electrophysiology lab are being transformed by novel tools. Technologies like Pulsed-Field Ablation, advanced, AI-assisted mapping systems, and leadless implantable devices present new therapeutic potentials but also new challenges and questions for the science around arrhythmia diagnostics, therapeutics, and overall understanding. This issue will focus on the pre-clinical, experimental, and translational aspects of these advancements. By highlighting the frontier of laboratory and experimental medicine in arrhythmology, this Special Issue hopes to pave the way for future, precision-based patient care.

Guest Editors

Dr. Panteleimon Pantelidis

Dr. Polychronis E. Dilaveris

Dr. Raffaele De Lucia

Dr. Evangelos Oikonomou

Deadline for manuscript submissions

30 June 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/261537

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).